THOR-707 + Pembrolizumab
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pleural Mesothelioma
Conditions
Pleural Mesothelioma, Non-small Cell Lung Cancer
Trial Timeline
Sep 23, 2021 → Oct 17, 2024
NCT ID
NCT04914897About THOR-707 + Pembrolizumab
THOR-707 + Pembrolizumab is a phase 2 stage product being developed by Merck for Pleural Mesothelioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04914897. Target conditions include Pleural Mesothelioma, Non-small Cell Lung Cancer.
What happened to similar drugs?
0 of 4 similar drugs in Pleural Mesothelioma were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05179603 | Phase 2 | Terminated |
| NCT04914897 | Phase 2 | Terminated |
Competing Products
20 competing products in Pleural Mesothelioma